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Celebrating the 25th anniversary of identifying the genetic cause of cystic fibrosis, 
tremendous progress has been made in the understanding and the treatment of this complex, 
but still fatal disease [1]. Despite advances, several key questions on the origins and 
pathomechanisms of CF remain poorly understood. For instance, the precise genetic and 
epigenetic mechanisms that regulate expression and stability of the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene remain incompletely defined.  
CFTR gene expression is a carefully controlled process that is spatially and temporally 
regulated. Notwithstanding the extensive research that has been carried out on CFTR over the 
past few decades, developmental control of CFTR expression is still poorly understood [2]. 
Transcription of CFTR starts at distinct sites depending on the tissue or developmental stage 
and is positively regulated by a selection of transcription factors, including C/EBP proteins 
and FOXA factors. Beyond that, CFTR is controlled post-transcriptionally by microRNAs 
(miRNAs). miRNAs are regulatory factors involved in most biological processes and it is 
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becoming increasingly clear that they play a key role in the development and manifestations 
of CF lung disease [3-13]. These small non-coding RNAs act post-transcriptionally to inhibit 
protein production. Their involvement in the pathogenesis of CF lung disease stems from the 
fact that their expression is altered in vivo in the CF lung due to intrinsic and extrinsic factors; 
to date defective chloride ion conductance, endoplasmic reticulum stress, inflammation and 
infection have been implicated in altering endogenous miRNA expression in this setting. 
 With their recent study, Viart et al. now expand substantially our understanding of 
how CFTR expression is regulated [14] (Figure 1). The authors identified regulatory elements 
that participate in CFTR downregulation, particularly FOXA1, FOXA2 and C/EBPα. Using 
bioinformatics, they further identified four new AU-rich elements (ARE) and experimentally 
tested their roles in regulation of CFTR expression. Following a series of intricate studies, 
ARE-5698 was found to play a role in destabilizing CFTR mRNA. Regarding miRNAs 
predicted to bind to the CFTR 3’UTR, miR-101 had the strongest repressive effect. By 
comparing miRNA expression profiles of adult and foetal lungs, three specific miRNAs 
(miR-145, miR-150 and miR-451) were found to have a temporal effect, being significantly 
up regulated in the adult lung and therefore contributing to downregulation of CFTR. 
 With a view to therapeutics that might enhance CFTR expression, miRNA binding-
blocker oligonucleotides (MBBOs, also known as target site blockers/protectors or miRNA 
masks) were designed. The function of an MBBO is to prevent binding of a miRNA to one 
specific mRNA target. Here MBBOs for several miRNAs that bind the CFTR 3’UTR were 
tested in vitro and ex vivo using non-CF and p.Phe508del homozygous CF primary human 
nasal epithelial cells grown at an air-liquid interface. MBBOs targeting the miR-145 and 
miR-101 sites were most effective, as they stabilised CFTR mRNA and enhanced CFTR 
protein expression. Finally, both MBBOs significantly enhanced CFTR function in 
CFBE41o- cells.  
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 This report adds significantly to our existing knowledge regarding miRNA regulation 
of CFTR [5-10, 13] and the developing field of miR-based CFTR therapeutics [15]. The data 
confirms previous studies implicating miR-145 and miR-101 as important modulators of 
CFTR expression [5, 6, 8, 9] and build on these by demonstrating how MBBOs based on 
these miRNAs can affect CFTR gene expression and CFTR protein function. The authors 
suggest that the MBBOs may be developed as tools for CFTR correction in people with CF. 
Indeed this is an appealing option given that MBBOs are less likely to have off-target effects 
compared to some other miRNA inhibition strategies [reviewed in 16]. 
 Although there are a series of novel findings from this paper, the work also raises a 
number of important questions for further investigation. The CF lung is inherently associated 
with microbial colonisation. Whether infection impacts upon the newly described 
transcriptional and post-transcriptional mechanisms controlling CFTR expression remains 
elusive. This will be particularly important for the further development of the MBBOs as 
therapeutics for CF. Previous studies have reported how infection and inflammation affect the 
expression of miRNAs, including those that regulate CFTR [9, 13]. This suggests that higher 
than normal levels of MBBOs may be required to ensure an inhibitory effect on endogenous 
miRNA activity. Nonetheless it will be a very exciting development when miRNA-
modulating drugs for CF advance to the stage of clinical studies. A second point worth 
considering is the relevance of Viart et al.’s findings beyond CF. Separate sets of studies 
have clearly shown that cigarette smoke affects CFTR and miRNA expression. Although the 
mechanisms responsible for altered CFTR expression in, for example, the COPD lung are not 
restricted to miRNA-mediated effects [17], miR-101 in particular is known to be increased by 
cigarette smoke extracts (CSE) and directly impacts on CFTR expression [8]. Finally, it is 
becoming increasingly evident that dysfunctional CFTR as a result of cigarette smoking can 
contribute to the pathophysiology of a range of extrapulmonary disease conditions, such as 
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chronic pancreatitis, male infertility and cachexia [18]. Expanding upon the findings from 
airway epithelial cells reported here into non-lung cells that express CFTR may yield novel 
therapies for these disease conditions beyond CF. 
 
FIGURE LEGENDS 
Figure 1. Transcriptional and post-transcriptional regulation of CFTR. In the adult lung (A) 
the transcription factors FOXA1/2 and C/EBPα negatively regulate CFTR gene expression 
whilst (B) ARE-5698 destabilises CFTR mRNA and miR-145 and miR-101 block CFTR 
expression. MBBOs targeting the miR-145 and miR-101 sites can restore CFTR expression. 
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